Evidence map›Paper›PMID 39808395›Full record

ArticleBreast cancer (Tokyo, Japan)2025

Tetraspanins CD63 and CD81 as potential prognostic biomarkers in breast cancer.

Erina Iwabuchi, Yasuhiro Miki, Junyao Xu, Ayako Kanai, Takanori Ishida, Takashi Suzuki

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Erina IwabuchiDepartment of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, Sendai, Japan. iwabuchi.erina@tmd.ac.jp.ORCID http://orcid.org/0000-0002-9838-7500
Yasuhiro MikiDepartment of Anatomic Pathology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Junyao XuThe Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, 310022, Zhejiang, China.
Ayako KanaiDepartment of Breast Surgery, Hachinohe City Hospital, Aomori, Japan.
Takanori IshidaDepartment of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Takashi SuzukiDepartment of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Funding

Japan Society for the Promotion of Science 19K16548
6 · The paper itself

Abstract

Exosome markers, CD63 and CD81, belong to the tetraspanin family and are expressed in solid tumors. It has been reported that these tetraspanin family members are prognostic factors in some cancers. However, the expression of CD63 and CD81 in pathological breast cancer specimens has not been reported. It has been reported that CD63 promotes the proliferation of breast cancer cells in vitro through yes-associated protein (YAP). Therefore, in this study, the expression of tetraspanin family members, particularly CD63, CD81, and YAP were investigated in breast cancer tissue, by immunohistochemistry, to clarify the relationship between clinicopathological factors and prognosis. The number of CD63 and YAP double-positive breast cancer cells was significantly higher in patients with pathological T factor (pT) status (p = 0.030) and tended to be higher in patients with pathological N factor (pN) status (p = 0.054). Furthermore, the number of CD81 and YAP double-positive breast cancer cells was significantly higher in patients with histological grade (p = 0.015), pT status (p = 0.001), and Ki67 expression (p = 0.049), and tended to be higher in patients with pN status (p = 0.062) and TNM stage (p = 0.052). In addition, CD63 and YAP double-positive breast cancers and CD81 and YAP double-positive breast cancers were associated with shorter disease-free and breast cancer-specific survival, respectively. In conclusion, CD63 and YAP, and CD81 and YAP may serve as potential prognostic biomarkers in patients with breast cancer.

Indexed as

Biomarkers, TumorBreast NeoplasmsTetraspanin 28Tetraspanin 30Adaptor Proteins, Signal TransducingAdultAgedFemaleHumansMiddle AgedPrognosisTranscription FactorsYAP-Signaling ProteinsAdaptor Proteins, Signal TransducingBiomarkers, TumorCD63 protein, humanCD81 protein, humanTetraspanin 28Tetraspanin 30Transcription FactorsYAP1 protein, humanYAP-Signaling ProteinsBreast cancerPrognostic biomarkersTetraspanin familyYes-associated protein

Identifiers

PMID39808395

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.